European Commission approves LORVIQU for certain adult patients with previously-treated ALK-positive NSCLC
“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient care with the approval of LORVIQUA,” said